Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16393157 | 1.00 | DPP4 (0.42) | DPP4PDK2LMNACYP2C19HSD17B10 | |
| SCHEMBL30644689 | 0.89 | DPP4 (0.33) | DPP4PDK2LMNACYP2C19HSD17B10 | |
| SCHEMBL1681427 | 0.83 | LMNA (0.58) | LMNACYP2C19HSD17B10ACE | |
| SCHEMBL7380987 | 0.83 | LMNA (0.58) | LMNACYP2C19HSD17B10ACE | |
| SCHEMBL1681430 | 0.83 | LMNA (0.58) | LMNACYP2C19HSD17B10ACE | |
| SCHEMBL30305372 | 0.82 | HTT (0.45) | DPP4LMNACYP2C19HSD17B10ACE | |
| SCHEMBL8591233 | 0.82 | HTT (0.45) | DPP4LMNACYP2C19HSD17B10ACE | |
| SCHEMBL3817074 | 0.82 | HTT (0.45) | DPP4LMNACYP2C19HSD17B10ACE | |
| SCHEMBL2036130 | 0.81 | LMNA (0.41) | LMNACYP2C19HSD17B10ACE | |
| SCHEMBL247604 | 0.81 | LMNA (0.41) | LMNACYP2C19HSD17B10ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006033796-A1 | SUBSTITUTED PYRAZOLO [1,5-a] PYRIMIDINES AND PROCESS FOR MAKING SAME | WYETH (US) | 2006-03-30 | — | — | WO | claimed |
| EP-3275861-A1 | TETRACYCLINE COMPOUNDS | Tetraphase Pharmaceuticals, Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| US-20170334841-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
| EP-2470500-B1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2017-10-04 | — | — | EP | disclosed |
| US-9624166-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9309285-B2 | Macrocyclic broad spectrum antibiotics | RQX PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| WO-2014081886-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20140142029-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20120208788-A1 | Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-08-16 | — | — | US | disclosed |
| EP-1697312-B1 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2011-07-20 | — | — | EP | disclosed |
| US-5364942-A | Treatment of hypertension and atherosclerosis | BAYER AKTIENGESELLSCHAFT (DE) | 1994-11-15 | — | — | US | disclosed |
| US-5318980-A | Antihypertensive and antiatherosclerotic agents | BAYER AKTIENGESELLSCHAFT (DE) | 1994-06-07 | — | — | US | disclosed |
| US-5254543-A | Hypotensive, anticholesterol agents | BAYER AKTIENGESELLSCHAFT (DE) | 1993-10-19 | — | — | US | disclosed |
| EP-0564788-A2 | Sulfonylbenzyl substituted imidazopyridines as AII-antagonists | BAYER AG (DE) | 1993-10-13 | — | — | EP | disclosed |
| EP-0562261-A2 | Sulphonylbenzyl substituted imidazoles | BAYER AG (DE) | 1993-09-29 | — | — | EP | disclosed |
| EP-0557843-A2 | Sulfonylbenzyl-substituted pyridones as pharmaceuticals | BAYER AG (DE) | 1993-09-01 | — | — | EP | disclosed |
| EP-0557842-A2 | Sulphonylbenzyl substituted imidazolylpropenic acid derivatives | BAYER AG (DE) | 1993-09-01 | — | — | EP | disclosed |
| US-4091029-A | RESOLVING AGENT FOR RACEMIC MIXTURES | ELI LILLY AND COMPANY (US) | 1978-05-23 | — | — | US | disclosed |
| US-4000197-A | FROM PHENYLACETONES AND METHYL BENZYLAMINE, REDUCTION, HYDROGENOLYSIS | THE UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1976-12-28 | — | — | US | disclosed |
| US-3972925-A | RESOLUTION AGENT | ELI LILLY AND COMPANY (US) | 1976-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142029-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | DPP4 58/4885PDK2 3915/4885LMNA 1857/4885 |
| US-20170334841-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1A, TUBA1C | DPP4 1480/4885PDK2 4230/4885LMNA 3276/4885 |
| US-20120208788-A1 | Tetracycline Compounds | TUBA1A, TUBA1C, TUBB1 | DPP4 1551/4885PDK2 4252/4885LMNA 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.